Technical Analysis for IMV - IMV Inc

Grade Last Price % Change Price Change
grade D 2.75 -4.51% -0.1300
IMV closed down 4.51 percent on Friday, September 27, 2019, on 1.13 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
See historical IMV trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Down 3 Days in a Row Weakness 0.00%
New 52 Week Closing Low Bearish -4.51%
Hot IPO Pullback Bullish Swing Setup -4.51%
New 52 Week Low Weakness -4.51%
New 52 Week Closing Low Bearish -8.03%
New 52 Week Low Weakness -8.03%
Gapped Down Weakness -8.03%
Gapped Up Strength -51.50%
Outside Day Range Expansion -50.09%
Older signals for IMV ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is based in Dartmouth, Canada.
Medicine Medical Specialties Cancer Clinical Medicine Immunotherapy Cancer Immunotherapy Ovarian Cancer Vaccines Lymphoma Cancer Therapy Treating Cancer Malaria Hpv Therapies For Cancer Lead Cancer

Is IMV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.0
52 Week Low 2.59
Average Volume 3,403
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 4.7319
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line -0.1631
MACD Signal Line -0.0326
MACD Histogram -0.1305
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.0350
Resistance 3 (R3) 3.0667 3.0033 2.9875
Resistance 2 (R2) 3.0033 2.9308 2.9875 2.9717
Resistance 1 (R1) 2.8767 2.8859 2.8450 2.8450 2.9558
Pivot Point 2.8133 2.8133 2.7975 2.7975 2.8133
Support 1 (S1) 2.6867 2.7408 2.6550 2.6550 2.5442
Support 2 (S2) 2.6233 2.6959 2.6075 2.5283
Support 3 (S3) 2.4967 2.6233 2.5125
Support 4 (S4) 2.4650